The mixture of anti-TIGIT antibody vibostolimab, Keytruda and chemotherapy didn’t enhance total survival in contrast with Tecentriq and chemotherapy in sufferers with extensive-stage small-cell lung most cancers.
Remedy with the anti-TIGIT antibody vibostolimab and Keytruda (pembrolizumab) plus etoposide and platinum didn’t enhance total survival versus Tecentriq (atezolizumab) plus etoposide and platinum in sufferers with extensive-stage small cell lung most cancers (SCLC), based on knowledge from a part 3 trial introduced on the 2024 SITC Annual Assembly.
As frontline remedy, the investigational routine led to a median total survival of 11.5 months versus 12.9 months with the management routine. Median progression-free survival was 5.3 months versus 4.5 months, respectively.
“Based mostly on the profit/threat profile noticed, remedy with vibostolimab/[Keytruda] was discontinued within the KEYVIBE-008 trial,” Dr. Jacob Sands, lead research writer, assistant professor at Harvard Medical Faculty, and Oncology Medical Director of the Worldwide Affected person Middle at Dana-Farber Most cancers Institute in Boston, mentioned in a presentation of the info. “Investigation of vibostolimab/[Keytruda] is ongoing in non–small cell lung most cancers [NSCLC].”
The announcement of the trial’s discontinuation was first made in August 2024 in accordance with the advice from an impartial knowledge monitoring committee.
Glossary:
Anti-TIGIT antibody: a kind of immunotherapy that targets the protein, TIGIT, discovered on immune cells.
Frontline remedy: the primary course of remedy used to deal with a illness.
Partial response: a lower in tumor dimension or extent of most cancers all through the physique.
Goal response fee: share of sufferers with a partial or full response from remedy.
Length of response: the time from the beginning of remedy till when the illness progresses, or the affected person dies.
General survival: the time when a affected person with most cancers remains to be alive.
Development-free survival: the time when a affected person with most cancers lives with out illness worsening.
Leukopenia: lower-than-normal variety of leukocytes, a kind of white blood cell.
Metastatic: spreading of illness.
Further efficacy outcomes revealed that the six- and 12-month total survival charges with the investigational routine have been 78.7% and 49.1%, respectively, and 87.4% and 55%, respectively, with the management routine. The six- and 12-month progression-free survival charges within the investigational group have been 30% and 12.4%, respectively, and 26.5% and 13.3%, respectively, within the management group.
The target response fee was 71.7% within the investigational group versus 74.8% within the management group. The median length of response was 4.2 months with vibostolimab/Keytruda versus 3.9 months with Tecentriq. Within the investigational group, finest responses included full response (6.1%), partial response (65.7%), secure illness (15.7%) and progressive illness (4.8%). Within the management group, finest responses included full response (6.1%), partial response (68.7%), secure illness (13.5%) and progressive illness (5.2%).
Regardless of the trial’s outcomes, there had been substantial proof in assist of the routine’s potential efficacy, together with findings from the part 3 KEYNOTE-604 trial. These findings confirmed improved progression-free survival, although not total survival, with the primary line of remedy mixture of Keytruda and etoposide and platinum in SCLC.
“Grade 3 or better [treatment-related side effects] and immune-mediated [side effects] have been extra frequent with vibostolimab/Keytruda versus [Tecentriq], per twin immune checkpoint inhibitor remedy,” Sands mentioned. He added that no new security indicators have been recognized.
Widespread treatment-related unwanted side effects within the investigational group have been anemia, low white blood cell rely, leukopenia, hair loss, low platelet rely, nausea, decreased urge for food, constipation, fatigue, weak point, rash and itching.
Immune-mediated unwanted side effects and infusion reactions included underactive thyroid, overactive thyroid, infusion reactions, lung irritation, irritation of the pancreas, adrenal insufficiency, irritation of colon, extreme pores and skin reactions, kind 1 diabetes, irritation of the pituitary gland, mind irritation, hepatitis and abdomen irritation.
The median length of remedy was 4.9 months within the investigational group versus 4.9 months within the management group. Most treatment-related unwanted side effects have been between grade 3 (extreme) and 5 (lethal) within the investigational (66.8%) and management (57.2%) teams. Remedy-related unwanted side effects resulting in discontinuation of any remedy or demise occurred in 11.8% and 1.7% of sufferers, respectively, within the investigational group, and 6.6% and 0.9%, respectively, of sufferers within the management group. Extreme, life-threatening, or demise inflicting immune-mediated unwanted side effects and infusion reactions occurred in 14.8% of sufferers within the investigational group versus 3.5% within the management group; 0.9% of occasions led to demise within the investigational group.
KEYVIBE-008 was a trial that enrolled sufferers a minimum of 18 years of age with newly identified, beforehand untreated extensive-stage SCLC and measurable illness.
Within the investigational group the median affected person age was 64 years and 67% of sufferers have been males. Most sufferers have been present or former people who smoke (91.7%). The vast majority of sufferers additionally had stage 4B illness (60%), lactate dehydrogenase above the higher restrict of regular (60%) and a minimum of three metastatic websites (78.3%). Median tumor dimension was 142 millimeters.
The median time from remedy project to knowledge cutoff was 16.6 months. Of the 230 sufferers who had been randomly assigned, 229 began remedies in every group. At knowledge cutoff, 16 sufferers within the investigational group and 29 within the management group have been in ongoing remedy.
For extra information on most cancers updates, analysis and training, don’t overlook to subscribe to CURE®’s newsletters right here.
